There are 2949 resources available
314P - Real-world (RW) multi-country study of BRCA1/2 testing in adult patients (pts) with HER2−advanced breast cancer (ABC)
Presenter: Michael Patrick Lux
Session: E-Poster Display
Resources:
Abstract
316P - Real-world treatment patterns and clinical effectiveness outcomes of eribulin in metastatic breast cancer patients in community oncology centers in the United States
Presenter: Sarah Mougalian
Session: E-Poster Display
Resources:
Abstract
317P - Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial
Presenter: Nadia Califaretti
Session: E-Poster Display
Resources:
Abstract
318P - The real-world Hellenic disease management patterns with everolimus (EVE) for women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (aBC): ‘The MIRROR’ study
Presenter: Flora Zagouri
Session: E-Poster Display
Resources:
Abstract
319P - Prognosis for patients with oligometastatic breast cancer who achieve NED status after systemic and local therapy
Presenter: Ernesto Olcina Aguado
Session: E-Poster Display
Resources:
Abstract
320P - Oligometastatic breast cancer incidence and clinical presentation at diagnosis: About 131 cases
Presenter: Jean Louis Lacaze
Session: E-Poster Display
Resources:
Abstract
321P - First-line treatment patterns in HR+/HER2- locally advanced or metastatic breast cancer in Europe
Presenter: Katie Lewis
Session: E-Poster Display
Resources:
Abstract
322P - Prognostic factors for overall survival (OS) in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Analyses from PALOMA-3
Presenter: Hope Rugo
Session: E-Poster Display
Resources:
Abstract
323P - A retrospective study of evaluating the status and security of re-biopsy in advanced breast cancer
Presenter: Huimin Lv
Session: E-Poster Display
Resources:
Abstract
324P - What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL
Presenter: Anja Welt
Session: E-Poster Display
Resources:
Abstract